keytruda global sale
conclus raised/narrow sale rang
maintain yoy midpoint vs our/street
narrow rais ep rang
midpoint yoy prior vs our/
street higher gross margin high tax rate sale
yoy report ex-fx our/street
solid keytruda gardasil beat ep
yoy beat strh/street lower cog lower opex sg
keytruda sale us beat our/street est
larg us strength establish
leadership posit nsclc highli competit wall data
expect keytruda reach us io sale see note titl us
io market mom adj sept opdivo/keytruda show upside/downsid
oncolog posit strengthen astrazeneca azn rate
eisai rate partnership allianc revenu expect
addit deal mrk transit away primari
sale vs toward specialti sale oncolog
vaccin anim health ah support long-
term ebitda margin see note titl deep dive support oper
margin expans rais pt capit alloc mrk
increas dividend vs annual increas last year
top repo last month net option also increas
project capital-expenditure feb reiter buy/
ep support dcf risk pt includ
clinical/regulatori risk commerci downsid in-lin januvia life-
cycl gardasil product well new launch keytruda pipelin asset
narrow sales/rais ep yoy midpt
narrow revenu rang
midpoint unchang yoy vs our/street
expect minim fx impact sale vs prior
assumpt slightli favor continu expect opex
low- mid-singl digit yoy vs our/street rais tax
rate rang midpoint vs our/
street narrow rais ep rang
midpoint yoy vs our/street mrk rang assum ep impact
fx consist prior assumpt assum unchang revenu midpoint
unchang opex assumpt higher tax rais ep midpoint impli expect
higher gross margin expect comment gross margin expect
call exhibit summari mrk rang vs our/street estim
capit alloc increas dividend board author new
stock purchas program time limit enter acceler
total revenu came yoy report constant currenc
vs our/street estim us sale yoy estim
revenu miss estim oncolog global sale keytruda
yoy our/street us sale beat
model assum keytruda overtak bristol-my buy opdivo us market leader
driven leadership nsclc report allianc revenu oncolog miss
our/street note come esmo click see signific long-
term growth opportun lynparza lenvima put upward pressur our/street
allianc revenu outsid oncolog gardasil sale came beat our/
street estim easier comp headwind june
cyber-attack januvia sale miss our/street estim anim
ah sale came yoy our/street
ah segment profit margin key miss our/
street est includ zetia vytorin ex-u weak
cardiovascular brand face loss exclus mrk product miss includ bridion
exhibit summari sale vs our/street est
sale miss street ep beat ex
total revenu our/street gross
margin report our/street op-ex sg
our/street modestli
our/street estim mrk tax rate vs our/street
ep came yoy our/street estim compar
estim lower cog lower sg contribut ep beat partial
off-set lower sale higher exhibit summari pnl
catalyst focus keytruda pipelin asset
success esmo click also present data
tigit washington dc mrk pivot
studi keytruda inlyta rcc met primari endpoint os/pf interim
expect full data atlanta ga like file keytruda
inlyta global regul rcc near-term azn/mrk lynparza brca ovarian cancer
dataset present esmo roy bayn said /azn work
regulatori author quickli possibl seek approv lynparza patient expect
approv mainten set fda action expect near-term keytruda
withdrew sbla keytruda head neck cancer impress
data esmo posit transit earlier line therapi see note upcom notabl
data read-out keytruda includ neoadj /adj tnbc tnbc dec
chl dec gastric mono/combo feb feb
page
page
rang rang rang rang rang midpointsstrh estimatesconsensu fx impact gross margin slightli lower yoy slightli lower yoy lower yoy providednot admin providednot providednot providednot providednot providednot providednot providednot providednot oper expensesup low-to-mid singl digitsup low-to-mid singl digitsup low-to-mid singl digitsup low-to-mid singl low-to-mid-singl digit oper incomenot providednot providednot providednot providednot expens providednot providednot providednot providednot incomenot providednot providednot providednot providednot net incomenot providednot providednot providednot providednot fxdilut share yellow indic updat merck co inc
page
actualvari vs strhepsconsensusactualno ofdeltadelta cig cig yoyu cardiovascular vytorin gener medicin nuvar implanon cozaar hyzaar follistim nasonex dulera specialtyvirolog isentress acut bridion sugammadex noxafil invanz primaxin gardasil proquad m-m-r ii revenu actualstrh estimatesvari vs strhepsconsensusactualno ofdeltadelta cig cig yoyu incom interest dilut share actualstrh estimatesvari vs strhepsconsensusactualno ofdeltadeltamargin diff yoy margin margin estim merck co inc
valuat risk
target price assum merck trade ep estim support
discount cash flow dcf model multipl ep group averag
think appropri given mrk leadership immuno-oncolog space keytruda
first-mov advantag nsclc
risk rate target price includ failur capit truda first-mov advantag
nsclc approv use januvia franchis see materi declin sale due rise
competit oral dpp-iv segment clinic regulatori risk keytruda
relebactam infect herp zoster valent pneumococc vaccin
global price risk invest risk relat biopharmaceut industri includ global price risk
payer polit risk clinic develop risk regulatori risk commerci risk legal
risk patent challeng
compani mention note
astrazeneca azn rate
eisai rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
